{"product_id":"harmonybiosciences-business-model-canvas","title":"Harmony Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHarmony's Business Model: A Deep Dive\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the strategic blueprint behind Harmony's success with our comprehensive Business Model Canvas. This detailed document breaks down their customer segments, value propositions, and revenue streams, offering invaluable insights for your own venture. Discover the core components that drive their market leadership and gain a competitive edge.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Licensing Agreements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHarmony Biosciences leverages strategic licensing agreements to broaden its product offerings and development pipeline. These partnerships are crucial for accessing novel technologies and compounds that complement its internal research efforts.\u003c\/p\u003e\n\u003cp\u003eA prime example is the sublicense agreement with Bioprojet for BP1.15205, an orexin-2 receptor agonist. This specific deal significantly impacted Harmony's financial activities, contributing to a notable increase in their research and development expenses during 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch Collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHarmony actively pursues research collaborations to deepen its knowledge and accelerate the development of novel therapies for rare neurological disorders. These partnerships are crucial for accessing specialized expertise and cutting-edge technologies, thereby enhancing the company's innovation pipeline.\u003c\/p\u003e\n\u003cp\u003eA prime illustration of this strategy is Harmony's recent collaboration with CiRC Biosciences. This partnership specifically targets advancements in regenerative medicine, aiming to develop treatments for conditions like treatment-resistant epilepsy and narcolepsy, areas with significant unmet medical needs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Research Organizations (CROs)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHarmony collaborates with Contract Research Organizations (CROs) to manage its critical clinical trials, ensuring efficient and compliant drug development. These partnerships are particularly vital for Harmony's late-stage pipeline, which includes promising candidates like ZYN002, Pitolisant-HD, and EPX-100.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Provider Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHarmony's success hinges on robust partnerships with healthcare provider networks, critical for both commercializing its treatments and reaching patients effectively. These collaborations are the backbone of ensuring broad clinical utility and patient access to its key product, WAKIX.\u003c\/p\u003e\n\u003cp\u003eThe company actively cultivates relationships with a substantial number of healthcare professionals. As of recent data, Harmony engages with approximately 9,000 healthcare professionals. This extensive network is vital for driving adoption and ensuring that patients who can benefit from WAKIX have access to it.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eExtensive Reach:\u003c\/strong\u003e Engagement with ~9,000 healthcare professionals facilitates widespread clinical utility.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Access:\u003c\/strong\u003e Strong provider relationships are key to ensuring patient access to WAKIX.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCommercialization Support:\u003c\/strong\u003e These partnerships are fundamental for the effective commercialization of Harmony's therapies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy Groups\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHarmony's key partnerships with patient advocacy groups are crucial for understanding the specific needs of individuals with rare neurological diseases. These collaborations foster trust and provide invaluable insights into the patient journey. For instance, in 2024, Harmony actively engaged with groups supporting narcolepsy and Fragile X Syndrome patients, gathering feedback that directly informed their product development pipeline.\u003c\/p\u003e\n\u003cp\u003eThese partnerships are instrumental in developing effective patient education and support programs. By working with advocacy organizations, Harmony can ensure that information and resources are delivered in a sensitive and accessible manner. This approach was particularly evident in their 2024 outreach, where they co-created educational materials that reached over 15,000 patients and caregivers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eUnderstanding Unmet Needs:\u003c\/strong\u003e Direct engagement with patient advocacy groups in 2024 provided Harmony with critical feedback on existing treatment gaps for conditions like narcolepsy.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBuilding Trust:\u003c\/strong\u003e Collaborations with these groups helped establish Harmony as a trusted partner within the rare neurological disease communities.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePatient Education and Support:\u003c\/strong\u003e Partnerships facilitated the creation of targeted educational materials and support networks, enhancing patient care in 2024.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCommunity Engagement:\u003c\/strong\u003e Advocacy groups acted as vital conduits for reaching and engaging with patient populations, amplifying Harmony's impact.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Alliances Accelerate Neurological Disease Discoveries\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHarmony's key partnerships extend to academic institutions, fostering research into rare neurological diseases. These collaborations are vital for scientific validation and the exploration of new therapeutic targets, as seen in their ongoing work with leading universities. For example, a 2024 research grant awarded to a university partner focused on understanding the genetic underpinnings of narcolepsy, a condition Harmony actively addresses.\u003c\/p\u003e\n\u003cp\u003eThese academic alliances are crucial for translating fundamental scientific discoveries into potential clinical applications. By leveraging the expertise of academic researchers, Harmony can accelerate its innovation cycle and explore novel treatment modalities. This approach ensures a continuous influx of promising early-stage research that can feed into their development pipeline.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003ePartner Type\u003c\/th\u003e\n\u003cth\u003eExample Partnership\u003c\/th\u003e\n\u003cth\u003eKey Contribution\u003c\/th\u003e\n\u003cth\u003e2024 Impact\/Focus\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing\u003c\/td\u003e\n\u003ctd\u003eBioprojet (sublicense for BP1.15205)\u003c\/td\u003e\n\u003ctd\u003eAccess to novel orexin-2 receptor agonist\u003c\/td\u003e\n\u003ctd\u003eIncreased R\u0026amp;D expenses\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch Collaboration\u003c\/td\u003e\n\u003ctd\u003eCiRC Biosciences\u003c\/td\u003e\n\u003ctd\u003eAdvancements in regenerative medicine for epilepsy and narcolepsy\u003c\/td\u003e\n\u003ctd\u003eTargeted development for unmet needs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCROs\u003c\/td\u003e\n\u003ctd\u003eClinical Trial Management\u003c\/td\u003e\n\u003ctd\u003eEfficient and compliant drug development\u003c\/td\u003e\n\u003ctd\u003eSupport for late-stage pipeline (ZYN002, Pitolisant-HD, EPX-100)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealthcare Providers\u003c\/td\u003e\n\u003ctd\u003eProvider Networks\u003c\/td\u003e\n\u003ctd\u003eCommercialization and patient access to WAKIX\u003c\/td\u003e\n\u003ctd\u003eEngagement with ~9,000 healthcare professionals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient Advocacy\u003c\/td\u003e\n\u003ctd\u003eNarcolepsy \u0026amp; Fragile X Groups\u003c\/td\u003e\n\u003ctd\u003eUnderstanding patient needs, education programs\u003c\/td\u003e\n\u003ctd\u003eCo-created educational materials reaching 15,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademic Institutions\u003c\/td\u003e\n\u003ctd\u003eUniversity Research Grants\u003c\/td\u003e\n\u003ctd\u003eScientific validation, new therapeutic targets\u003c\/td\u003e\n\u003ctd\u003eNarcolepsy genetic research\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA strategic framework that visually maps a company's business model, detailing key partners, activities, resources, cost structure, and revenue streams.\u003c\/p\u003e\n\u003cp\u003eEnables a holistic understanding of how a business creates, delivers, and captures value, facilitating strategic planning and innovation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eAddresses the pain of strategic ambiguity by providing a structured framework to identify and map key business elements, thereby clarifying direction.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development of Novel Therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHarmony Biosciences actively pursues the discovery and development of innovative treatments for rare neurological conditions, evidenced by its robust pipeline.  In 2023, the company reported significant progress in advancing multiple programs, including those targeting Fragile X syndrome and idiopathic hypersomnia, demonstrating a commitment to addressing unmet medical needs in these areas.\u003c\/p\u003e\n\u003cp\u003eThe company's research and development efforts are focused on creating novel therapeutic solutions for a range of rare epilepsies, aiming to improve patient outcomes. Harmony Biosciences' strategic investment in R\u0026amp;D underscores its dedication to building a multi-franchise portfolio designed to tackle complex neurological disorders.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trial Execution and Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHarmony Business Model Canvas's key activity revolves around the meticulous execution and management of clinical trials. This involves designing, implementing, and overseeing studies to gather robust data on their investigational therapies.\u003c\/p\u003e\n\u003cp\u003eThe company is actively engaged in multiple Phase 3 programs, a critical stage for confirming the safety and efficacy of its drug candidates. For instance, in 2025, Harmony anticipates reporting topline data from its ZYN002 trial for Fragile X syndrome. This is a significant milestone, as positive results could pave the way for regulatory submission.\u003c\/p\u003e\n\u003cp\u003eFurthermore, Harmony is set to initiate Phase 3 trials for Pitolisant-HD in 2025. This expansion into a new indication underscores the company's commitment to addressing unmet medical needs through rigorous scientific validation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercialization and Sales of Approved Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHarmony's core activity revolves around the commercialization and sales of its approved products, with WAKIX (pitolisant) for narcolepsy being its flagship. This crucial phase involves robust marketing strategies, efficient distribution networks, and direct engagement with healthcare professionals to ensure widespread adoption and sustained revenue generation.\u003c\/p\u003e\n\u003cp\u003eIn 2024, Harmony reported WAKIX net sales of $937 million, a significant increase from $737 million in 2023, demonstrating successful market penetration and growth. The company actively works with physicians and patient advocacy groups to raise awareness and facilitate access to WAKIX, aiming to capture a larger share of the narcolepsy market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Management and Defense\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eProtecting its intellectual property is a core activity, especially for WAKIX. This involves strategic patent filings and robust enforcement to maintain market exclusivity for its approved therapies.\u003c\/p\u003e\n\u003cp\u003eSuccessful litigation settlements, like those seen in recent years, underscore the importance of this activity in securing long-term profitability. These actions directly contribute to the company's sustainable revenue streams and market position.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003ePatent Protection:\u003c\/strong\u003e Maintaining a strong portfolio of patents for WAKIX and other pipeline assets.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eLitigation and Enforcement:\u003c\/strong\u003e Actively defending patents against infringement to preserve market exclusivity.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eLicensing and Partnerships:\u003c\/strong\u003e Strategically managing IP through licensing agreements to expand market reach.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRegulatory Exclusivity:\u003c\/strong\u003e Leveraging regulatory pathways to further extend market protection beyond patent life.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Affairs and Approvals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNavigating the intricate regulatory environment is a core activity, involving the meticulous preparation and submission of New Drug Applications (NDAs) and Supplemental NDAs (sNDAs) to agencies like the U.S. Food and Drug Administration (FDA).\u003c\/p\u003e\n\u003cp\u003eThis ongoing process is vital for securing market authorization for novel therapies and expanded uses of existing treatments. In 2024, the FDA continued to streamline its review processes, with many novel drugs receiving approval within the target timeframe, reflecting the industry's commitment to innovation.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eRegulatory submissions for new drug applications (NDAs) and supplemental NDAs (sNDAs).\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eEngaging with regulatory bodies like the FDA to ensure compliance and address queries.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eSecuring approvals for new indications and product line extensions.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eMonitoring and adapting to evolving regulatory guidelines and requirements.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHarmony's Core Activities: Clinical Milestones \u0026amp; Market Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHarmony's key activities are centered on the rigorous clinical development of its investigational therapies, including the management of multiple ongoing clinical trials. This is complemented by the strategic commercialization and sales of its approved products, with WAKIX being a primary focus. A critical ongoing activity involves the robust protection and enforcement of its intellectual property portfolio to maintain market exclusivity and competitive advantage.\u003c\/p\u003e\n\u003cp\u003eThe company also actively navigates complex regulatory landscapes, ensuring compliance and seeking approvals for new indications and product extensions. These core functions are essential for Harmony's mission to deliver innovative treatments for rare neurological disorders.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eKey Activity\u003c\/th\u003e\n\u003cth\u003eDescription\u003c\/th\u003e\n\u003cth\u003e2024\/2025 Focus\/Data\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical Development\u003c\/td\u003e\n\u003ctd\u003eExecuting and managing clinical trials for pipeline assets.\u003c\/td\u003e\n\u003ctd\u003eAnticipated topline data from ZYN002 trial (Fragile X) in 2025; initiating Phase 3 for Pitolisant-HD in 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercialization \u0026amp; Sales\u003c\/td\u003e\n\u003ctd\u003eMarketing and selling approved therapies, primarily WAKIX.\u003c\/td\u003e\n\u003ctd\u003eWAKIX net sales reached $937 million in 2024, up from $737 million in 2023.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntellectual Property Protection\u003c\/td\u003e\n\u003ctd\u003eSecuring and defending patents to maintain market exclusivity.\u003c\/td\u003e\n\u003ctd\u003eOngoing patent filings and litigation to protect WAKIX and other assets.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory Affairs\u003c\/td\u003e\n\u003ctd\u003eNavigating regulatory processes for drug approvals and extensions.\u003c\/td\u003e\n\u003ctd\u003eSubmitting NDAs\/sNDAs; engaging with FDA to ensure compliance and approvals.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Harmony Business Model Canvas preview you're viewing is the exact document you will receive upon purchase. This means you're seeing the genuine structure, content, and formatting that will be delivered, ensuring no discrepancies or surprises. Upon completing your order, you'll gain full access to this same, ready-to-use Business Model Canvas, allowing you to immediately begin refining your business strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":55674778747257,"sku":"harmonybiosciences-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/harmonybiosciences-business-model-canvas.png?v=1755795260","url":"https:\/\/portersfiveforce.com\/products\/harmonybiosciences-business-model-canvas","provider":"Porter's Five Forces","version":"1.0","type":"link"}